中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2010年
7期
452-455
,共4页
结直肠癌%斑蝥%抗肿瘤联合化学治疗方案%肿瘤转移
結直腸癌%斑蝥%抗腫瘤聯閤化學治療方案%腫瘤轉移
결직장암%반모%항종류연합화학치료방안%종류전이
Colorectal neoplasms%Mylabris%Antineoplastic combined chemotherapy protocols%Neoplasm metastasis
目的 观察复方斑蝥胶囊联合奥沙利铂(L-OHP)、5-氟尿嘧啶/亚叶酸钙(5-FU/CF)组成的FOLFOX4方案治疗转移性结直肠癌的临床疗效及不良反应.方法 收集2006年4月至2008年10月收治的无手术指征的转移性结直肠癌患者107例,随机分为复方斑蝥胶囊联合FOLFOX4方案组(联合治疗组)54例和FOLFOX4方案组53例.联合治疗组给予L-OHP 85mg/m2,第1天静脉滴注2 h,同时或之后予CF 200 mg/m2,静脉滴注2 h,续5-FU 400 mg/m2静脉推注,600 mg/m2持续静脉滴注22 h,次目重复,CF与5-FU每2周重复一次,同时予以复方斑蝥胶囊口服750 mg,每天2次.FOLFOX4方案组患者单纯接受FOLFOX4方案化学治疗.结果 联合治疗组和FOLFOX4方案组有效率分别为44.4%和37.7%,两组间差异无统计学意义(P=0.481).联合治疗组的中位无进展时间(TTP)为11.6个月,FOLFOX4方案组为7.9个月,两组间差异有统计学意义(P=0.020).生活质量评价,联合治疗组的改善率为57.4%,FOLFOX4方案组为32.1%,两组间差异有统计学意义(P=0.008).两组不良反应主要表现为消化道反应、神经系统毒性、脱发和骨髓抑制.联合治疗组Ⅲ/Ⅳ度粒细胞减少发生率为37.0%,FOLFOX4方案组为58.5%,两组间差异有统计学意义(P=0.043).结论 复方斑蝥胶囊联合FOLFOX4方案一线治疗转移性结直肠癌能协同增效,能提高患者TTP及改善患者生活质量,降低粒细胞减少发生.
目的 觀察複方斑蝥膠囊聯閤奧沙利鉑(L-OHP)、5-氟尿嘧啶/亞葉痠鈣(5-FU/CF)組成的FOLFOX4方案治療轉移性結直腸癌的臨床療效及不良反應.方法 收集2006年4月至2008年10月收治的無手術指徵的轉移性結直腸癌患者107例,隨機分為複方斑蝥膠囊聯閤FOLFOX4方案組(聯閤治療組)54例和FOLFOX4方案組53例.聯閤治療組給予L-OHP 85mg/m2,第1天靜脈滴註2 h,同時或之後予CF 200 mg/m2,靜脈滴註2 h,續5-FU 400 mg/m2靜脈推註,600 mg/m2持續靜脈滴註22 h,次目重複,CF與5-FU每2週重複一次,同時予以複方斑蝥膠囊口服750 mg,每天2次.FOLFOX4方案組患者單純接受FOLFOX4方案化學治療.結果 聯閤治療組和FOLFOX4方案組有效率分彆為44.4%和37.7%,兩組間差異無統計學意義(P=0.481).聯閤治療組的中位無進展時間(TTP)為11.6箇月,FOLFOX4方案組為7.9箇月,兩組間差異有統計學意義(P=0.020).生活質量評價,聯閤治療組的改善率為57.4%,FOLFOX4方案組為32.1%,兩組間差異有統計學意義(P=0.008).兩組不良反應主要錶現為消化道反應、神經繫統毒性、脫髮和骨髓抑製.聯閤治療組Ⅲ/Ⅳ度粒細胞減少髮生率為37.0%,FOLFOX4方案組為58.5%,兩組間差異有統計學意義(P=0.043).結論 複方斑蝥膠囊聯閤FOLFOX4方案一線治療轉移性結直腸癌能協同增效,能提高患者TTP及改善患者生活質量,降低粒細胞減少髮生.
목적 관찰복방반모효낭연합오사리박(L-OHP)、5-불뇨밀정/아협산개(5-FU/CF)조성적FOLFOX4방안치료전이성결직장암적림상료효급불량반응.방법 수집2006년4월지2008년10월수치적무수술지정적전이성결직장암환자107례,수궤분위복방반모효낭연합FOLFOX4방안조(연합치료조)54례화FOLFOX4방안조53례.연합치료조급여L-OHP 85mg/m2,제1천정맥적주2 h,동시혹지후여CF 200 mg/m2,정맥적주2 h,속5-FU 400 mg/m2정맥추주,600 mg/m2지속정맥적주22 h,차목중복,CF여5-FU매2주중복일차,동시여이복방반모효낭구복750 mg,매천2차.FOLFOX4방안조환자단순접수FOLFOX4방안화학치료.결과 연합치료조화FOLFOX4방안조유효솔분별위44.4%화37.7%,량조간차이무통계학의의(P=0.481).연합치료조적중위무진전시간(TTP)위11.6개월,FOLFOX4방안조위7.9개월,량조간차이유통계학의의(P=0.020).생활질량평개,연합치료조적개선솔위57.4%,FOLFOX4방안조위32.1%,량조간차이유통계학의의(P=0.008).량조불량반응주요표현위소화도반응、신경계통독성、탈발화골수억제.연합치료조Ⅲ/Ⅳ도립세포감소발생솔위37.0%,FOLFOX4방안조위58.5%,량조간차이유통계학의의(P=0.043).결론 복방반모효낭연합FOLFOX4방안일선치료전이성결직장암능협동증효,능제고환자TTP급개선환자생활질량,강저립세포감소발생.
Objective To investigate the efficacy and side effects of Fufangbanmao capsules combined with FOLFOX-4 (Oxaliplatin + 5-fluorouracil /Calcium folinate) regimen in the treatment of metastatic colorectal cancer (MCC). Methods A total of 107 patients with previously untreated MCC, who were admitted to the hospital between April 2006 and October 2008, were randomly divided into combination group (n = 54) and chemotherapy group (n = 53). In combination group, patients received Fufangbanmao capsules (750 mg twice daily) and FOLFOX4 regimen (oxaliplatin 85 mg/m2 day 1, infusion of CF 200 mg/m2 for 2 hours followed by bolus 5-FU 400 mg/m2 and a 22-hour infusion of 5-FU 600 mg/m2 ). Whereas the patients in chemotherapy group were treated with FOLFOX4 regimen. Results The effective rate was 44. 4% in combination group and 37. 7% in chemotherapy group with no significant difference (P = 0. 481). The median time to progression (TTP) was 11. 6 and 7. 9 months in combination group and chemotherapy group, respectively, with significant difference (P=0. 020). The difference was found in improvement of quality of life (QOL) between combination group and chemotherapy group (57. 4% vs 32. 1 % , P=0. 008). The side effects in two groups included gastrointestinal toxicities, neuropathy, alopecia and bone marrow suppression. However, Ⅲ/Ⅳ neutropenia was significantly less in combination group(37. 0%) when compared with chemotherapy group (58. 5%, P = 0. 043). Conclusions In first-line treatment of MCC, Fufangbanmao capsules combined with FOLFOX4 regimen showed synergic and enhanced effect for improving TTP and QOL, and also reduced the incidence of neutropenia.
